LIVZON PHARMAC. GRP H YC1 Cash Flow-to-Debt Ratio
LIVZON PHARMAC. GRP H YC1 cash flow-to-debt ratio. LIVZON PHARMAC. GRP H YC1 (LP6) has a Cash Flow-to-Debt Ratio of 0.37x as of December 2025, meaning its operating cash flow of €3.15 Billion could theoretically repay 0% of its total liabilities (€8.44 Billion) in one year. Check LIVZON PHARMAC. GRP H YC1 earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of LIVZON PHARMAC. GRP H YC1 (2021–2025)
Cash flow-to-debt ratio of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. Historical debt coverage capacity for LIVZON PHARMAC. GRP H YC1 across 5 annual periods. Check LP6 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
LIVZON PHARMAC. GRP H YC1 Cash Flow-to-Debt Ratio by Year (2021–2025)
LIVZON PHARMAC. GRP H YC1 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for LIVZON PHARMAC. GRP H YC1. For the full cash flow conversion analysis, see LP6 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | €3.15 Billion | €8.44 Billion | ▲ +19.5% |
| 2024 | 0.31x | €2.98 Billion | €9.55 Billion | ▼ -1.3% |
| 2023 | 0.32x | €3.25 Billion | €10.28 Billion | ▲ +13.2% |
| 2022 | 0.28x | €2.77 Billion | €9.93 Billion | ▲ +18.3% |
| 2021 | 0.24x | €1.90 Billion | €8.06 Billion | — |